Answers are grounded in this paper and cite their sources.
Stem cell therapy offers potential for generating new muscle tissue in myocardial infarction, but requires validation of cell selection, delivery routes, and regulatory issues before clinical use.
Myocardial infarction causes death worldwide with the greatest incidence being in the United States. Although there have been many advances in myocardial re-perfusion strategies and novel pharmacological approaches, therapies for treating acute and chronic myocardial ischemic damage remain limited. This means that no currently available heart failure treatment has demonstrated an ability to generate new muscle tissue within the scared regions of the heart. Stem cell, however, offers new hope to patients who have otherwise limited choices. Therefore, this review aims at exploring the use and peculiarities of stem cell therapy for myocardial infarction. But the success of stem cell therapy for clinical use needs the validation of several issues ranging from selection of appropriate stem cells, routes of transfer, establishment of conducive trans-differentiation milieu with associated cytokines, means to evaluate/track response to cell therapy to compliance with regulatory and ethical issues besides addressing biological and technical issues surrounding stem cell therapy.
No takes yet. Share an insight, caveat, or question.
Gizaw Dabessa Satessa (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: